CD163 and neoplasm: Treatment with tumor secretions (TC group) altered several classical macrophage receptors/factors, including CD206, CD80, and CD163, in bone marrow-derived macrophages (macrophages φ, control group), and BAM15 treatment did not reverse tumor-induced macrophage differentiation (TC-BAM15 group) (Fig. S2E).